Movement disorders clinical practice · 2026
Peripheral Neuropathy during Subcutaneous Foslevodopa/Foscarbidopa Infusion in Parkinson's Disease: A Case Series.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vial-Daragon Lucie, Poncet-Megemont Louis, Derost Philippe, Beal Charlotte, Debilly Berengere, Marques Ana
Аннотация
BACKGROUND: Peripheral neuropathy has been described in Parkinson's disease (PD) patients receiving continuous levodopa delivery. Whether subcutaneous foslevodopa/foscarbidopa (fLD/fCD) infusion carries a similar risk remains unclear.
CASES: We report four PD patients treated with continuous subcutaneous fLD/fCD who experienced clinical and electrophysiological worsening of peripheral neuropathy after treatment initiation. At baseline, none reported functional neuropathic symptoms, although electrophysiological evidence of mild subclinical peripheral neuropathy and/or biochemical abnormalities was present. Neuropathic symptoms developed within a few months of fLD/fCD initiation and were associated with vitamin B6 and/or B12 deficiency and persistent hyperhomocysteinemia. In all cases, electrophysiological deterioration accompanied symptoms emergence.
CONCLUSIONS: Although causality cannot be established, these cases suggest that fLD/fCD infusion may be associated with aggravation of pre-existing peripheral neuropathy, despite non-enteral administration, supporting a potential systemic metabolic contribution. These findings underscore the importance of baseline assessment and longitudinal monitoring of peripheral nerve function and B-vitamin status in patients receiving fLD/fCD. Optimal vitamin supplementation strategies in this setting remain to be defined.
CASES: We report four PD patients treated with continuous subcutaneous fLD/fCD who experienced clinical and electrophysiological worsening of peripheral neuropathy after treatment initiation. At baseline, none reported functional neuropathic symptoms, although electrophysiological evidence of mild subclinical peripheral neuropathy and/or biochemical abnormalities was present. Neuropathic symptoms developed within a few months of fLD/fCD initiation and were associated with vitamin B6 and/or B12 deficiency and persistent hyperhomocysteinemia. In all cases, electrophysiological deterioration accompanied symptoms emergence.
CONCLUSIONS: Although causality cannot be established, these cases suggest that fLD/fCD infusion may be associated with aggravation of pre-existing peripheral neuropathy, despite non-enteral administration, supporting a potential systemic metabolic contribution. These findings underscore the importance of baseline assessment and longitudinal monitoring of peripheral nerve function and B-vitamin status in patients receiving fLD/fCD. Optimal vitamin supplementation strategies in this setting remain to be defined.